Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond

Core Viewpoint - Trevi Therapeutics (TRVI) is being initiated with a "Buy" rating due to its advancement in getting its lead program into phase 3 testing [2]. Company Overview - Trevi Therapeutics is positioned favorably in the biotech sector, with its lead program already progressing to phase 3 testing, indicating a strong potential for future growth and value creation [2]. Analyst Background - The analysis is provided by Terry Chrisomalis, who has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which offers in-depth analysis and a model portfolio of biotech stocks [2].